series-a
Stage
About
Ripple Therapeutics is a clinical-stage company developing polymer-free, prodrug-based sustained-release implants (the Epidel® platform) to provide long-duration, controllable delivery of ophthalmic therapeutics for retinal diseases and glaucoma. The company engineers prodrugs that undergo surface erosion to enable constant drug release and is pursuing partnerships and clinical programs for indications such as DME, RVO, dry AMD/GA and glaucoma.
Explore Ripple Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.